| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 45.87 | 20.8% | 267.0% |
| Total Income | 45.87 | 20.8% | 267.0% |
| Expenditure | 103.30 | 3.7% | 1.2% |
| PBT | — | ||
| Net Profit | -60.72 | 15.5% | 27.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.70 | 15.7% | 28.6% |
Syndax Reports Q3 2025 Financial Results: Revenue $45.9M, Up 21% Q/Q
04 May 2026 · 4 May, 8:19 am
Summary
Syndax Pharmaceuticals reported its financial results for the third quarter ended September 30, 2025. Total revenue for the quarter was $45.9 million, driven by $32.0 million in Revuforj net revenue and $13.9 million in Niktimvo collaboration revenue. Revuforj prescriptions increased by 25% over the second quarter, and Niktimvo net revenue was $45.8 million as reported by Incyte. The company's cash position is $456.1 million, which is expected to fund the company to profitability. Management highlighted the strong commercial and pipeline execution during the quarter.
Key Highlights
- 1
Syndax reported total revenue of $45.9 million for the third quarter of 2025, representing a 21% increase over the second quarter of 2025.
- 2
Revuforj net revenue reached $32.0 million in Q3 2025, with total prescriptions increasing by 25% compared to Q2 2025.
- 3
Niktimvo net revenue, reported by Incyte, was $45.8 million, contributing to $13.9 million in collaboration revenue for Syndax.
- 4
The company's cash, cash equivalents, and investments totaled $456.1 million, expected to fund the company to profitability.
- 5
Revuforj received FDA approval on October 24, 2025, for the treatment of R/R acute myeloid leukemia (AML) with a susceptible NPM1 mutation.
- 6
Revuforj was added to the NCCN Guidelines for R/R NPM1m AML on September 18, 2025.
- 7
Niktimvo prescriptions have shown rapid uptake across U.S. bone marrow transplant centers, with 80% of centers having placed orders.
Management Comments
Michael A. Metzger
“The third quarter was another remarkable period of commercial and pipeline execution for Syndax. Demand remained strong for Revuforj and Niktimvo with over $75 million in combined net sales for the quarter. We also furthered our leadership in menin inhibition with the addition of Revuforj to the NCCN Guidelines for R/R NPM1m AML in late September followed by FDA approval in late October. Our expansion into this second indication is underway and we are making great progress driving awareness and generating demand. Additionally, we continue to advance the development of both Revuforj and Niktimvo in the frontline setting, further unlocking their multi-billion-dollar potential.”
Informational and educational content only. Not investment advice.